Skip to main content
OpenTrials
Completed

NCT Number: NCT02772965

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone in inducing and maintaining steroid-free remission for children with Crohn's Disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pediatric Crohn's Disease

Age range

Up to 20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Children's of Alabama, Birmingham, Alabama, United States

Loading trial locations.

About this study

Overall study duration: 6 years Multi-center study: up to 42 centers

Number of subjects: 425 Duration of treatment for each subject: up to 156 weeks (3 years)

The primary endpoint is percent of patients who experienced treatment failure over time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pediatric Crohn's Disease (PCD) patients, < 21 years of age, ≥20 kg, initiating anti-TNF therapy with infliximab or adalimumab (including biosimilars).
  • Diagnosis of Crohn's Disease (CD) established confirmed by the treating clinician, and established by standard clinical criteria (radiography, endoscopy, histology).
  • Ability to provide parental permission and child assent (where applicable), or adult consent for patients ages 18-20.

Exclusion criteria

  • Prior use of anti-TNF or other biological therapy for CD
  • Lack of stable home address that study medications can be mailed to
  • Anticipated short length of follow up at study center (plans for family to move, transition to adult GI (gastrointestinal) provider, etc.). Patients expected to leave practice < 12 months from enrollment should not be enrolled.
  • Concurrent pelvic or abdominal abscess. A recent history of abdominal or pelvic abscess, which is controlled, does not exclude the subject.
  • Prior intra-abdominal surgery without a clinically significant relapse (i.e. patients starting on anti-TNF for post-op prophylaxis or for endoscopic recurrence only should not be included)
  • Receipt of a live virus vaccine within the last 30 days
  • Pregnancy, planning to become pregnant, or high risk of pregnancy as determined by the local investigator
  • Breastfeeding
  • Refusal to stay abstinent or utilize 2 forms of birth control while on study medication (for female patients)
  • BMI > 98% for gender and age
  • Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years). A recent history of basal cell or squamous cell carcinoma, which is considered surgically cured, does not exclude the subject.Those with a recent history of colonic adenoma or dysplastic lesions should be excluded.
  • Known high alcohol consumption (more than seven drinks per week)
  • Patients with serum albumin < 2.5 g/dl
  • Patients with white blood cell count (WBC) < 3.0 x109th/L
  • Patients with platelet count < 100 x109th/L
  • Patients with initial elevation of liver enzymes (AST or ALT) > 1.5 times above normal limit
  • Patients with known active infection with Clostridium difficile (C. difficile) (untreated infection based on clinician assessment does not apply to colonization or infection controlled with current or prior treatment.)
  • Patients with pre-existing hepatic disease
  • Patients with pre-existing renal dysfunction (creatinine > 0.8 for children age<10, creatinine > 1.2 mg/dl for children age 10-18, and creatinine > 1.5 mg/dl for adults age 18 years and older).
  • Patients with a pre-existing chronic lung disease other than well controlled asthma
  • Current treatment with one of the following drugs: Probenecid (Probalan), Acitretin (Soriatane), Streptozocin (Zanosar), Azathioprine (Imuran, Azasan), 6-mercaptopurine (Purinethol, Purixan)
  • Other concerns about the patient/family's ability to participate in the study

Treatment and study plan

methotrexate

Drug
  • Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to <40 kg, and 10 mg for children 20 to <30 kg.
  • A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).
  • A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.

Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.

Other names: Methotrexate Sodium

Sugar pill (placebo)

Other
  • Placebo for methotrexate: The weekly dose will mimic that of methotrexate.
  • Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).
  • A 1 mg dose of folic acid per day will be provided to maintain blinding.

Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.

Primary outcomes

  1. Percent of Participants Experiencing Treatment Failure

    Time frame: From randomization until treatment failure, assessed up to 3 years.

    Treatment failure is defined as follows:

    • Failure to achieve remission (short pediatric Crohn's disease activity index [SPCDAI] < 15) by the week 26 visit;
    • If study initiated on steroids, failure to complete steroid taper by week 16;
    • Short pediatric Crohn's disease activity index (SPCDAI) ≥ 15 attributed to active Crohn's disease, at two or more consecutive visits beyond the week 26 visit. Elevated SPCDAI (≥ 15) due to a non-Inflammatory Bowel Disease (IBD) reason does not count toward this outcome;
    • Hospitalization for active Inflammatory Bowel Disease or abdominal surgery after week 25;
    • Use of oral prednisone or prednisolone, enteral release budesonide, or intravenous (IV) methylprednisolone for over 10 weeks cumulatively, beyond week 16;
    • Discontinuation of anti-TNF agent and/or study drug for lack of effectiveness or toxicity.

Secondary outcomes

  1. Mean Patient Reported Outcome Measurement and Information System (PROMIS ) Pain Interference T-score-52 Weeks

    Time frame: Weeks 52 from randomization

    T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average pain interference and scores below 50 represent lower than average pain interference. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6.

    The investigators will compare the mean of PROMIS Pain Interference T-scores at week 52 between the treatment groups.

  2. Mean Patient Reported Outcome Measurement and Information System (PROMIS ) Pain Interference T-score-week 104

    Time frame: 104 weeks from randomization

    T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average pain interference and scores below 50 represent lower than average pain interference. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6.

    The investigators will compare the mean of PROMIS Pain Interference T-scores at week 104 between the treatment groups

  3. Mean PROMIS (Patient Reported Outcome Measurement and Information System) Fatigue T Score-week 52

    Time frame: Week 52 from randomization

    T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average fatigue and scores below 50 represent lower than average fatigue. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6.

    The investigators will compare the mean of PROMIS Fatigue T-scores at week 52 between the treatment groups

  4. Mean PROMIS (Patient Reported Outcome Measurement and Information System) Fatigue T Score-week 104

    Time frame: 104 weeks from randomization

    T-scores are a continuous variable. The mean in the general population is 50 (SD=10). Scores above 50 represent higher than average fatigue and scores below 50 represent lower than average fatigue. Minimal important differences (MIDs) for many PROMIS domains are in the range of 2 to 6.

    The investigators will compare the mean of PROMIS Fatigue T-scores at week 104 between the treatment groups

  5. Percent of Patients With Positive Anti-TNF Antibody

    Time frame: Between 6 months and 2 years from randomization

    Percent of patients with positive anti-TNF antibody will be compared between the two treatment groups using the chi-squared test.

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • Children's Hospital Medical Center, Cincinnati
  • Grifols Diagnostics Solutions, Inc
  • ImproveCareNow (ICN)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • National Institutes of Health (NIH)
  • Patient-Centered Outcomes Research Institute
  • The Leona M. and Harry B. Helmsley Charitable Trust

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy

Acronym: COMBINE

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
May 16, 2016
Registry last updated
Apr 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.